The online version of Fortune magazine has produced an article about the digital health revolution that discusses the contribution of Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant as a maintenance treatment for opioid addiction.
Probuphine, which was approved by the FDA last year, dispenses a drug called buprenorphine – itself an opioid, but one that doesn’t produce the sort of euphoric and addictive high that more powerful painkillers such as OxyContin and morphine do.
Rather than have patients take buprenorphine manually, Probuphine dispenses small amounts of the drug continually into the bloodstream, ensuring that people actually stick to their prescribed regimen. The device can be used for up to six months and then replaced.
The Fortune article also discusses how these automated, long-term delivery systems could make it easier to treat everything from brain diseases to diabetes and HIV/AIDS. Titan is currently developing an implant to treat Parkinson’s disease.
The article can be accessed here.
